Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial
-
Published:2023-05
Issue:
Volume:184
Page:10-20
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Kawakami HisatoORCID, Sunakawa YuORCID, Inoue EisukeORCID, Matoba Ryo, Noda KentaORCID, Sato Toshiyuki, Suminaka Chihiro, Yamaki Mami, Sakamoto YasuhiroORCID, Kawabata Ryohei, Ishiguro Atsushi, Akamaru Yusuke, Kito Yosuke, Yabusaki Hiroshi, Matsuyama JinORCID, Takahashi Masazumi, Makiyama AkitakaORCID, Hayashi Hidetoshi, Chamoto Kenji, Honjo Tasuku, Nakagawa Kazuhiko, Ichikawa Wataru, Fujii Masashi
Funder
Sysmex Corporation Ono Pharmaceutical
Subject
Cancer Research,Oncology
Reference32 articles.
1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021 2. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial;Kang;Lancet,2017 3. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer;Kim;Nat Med,2018 4. Analytical performance of a new automated chemiluminescent magnetic immunoassays for soluble PD-1, PD-L1, and CTLA-4 in human plasma;Goto;Sci Rep,2019 5. Soluble immune checkpoint molecules: serum markers for cancer diagnosis and prognosis;Chakrabarti;Cancer Rep,2019
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|